EnVivo names Christopher Burnley CBO
This article was originally published in Scrip
Executive Summary
EnVivo Pharmaceuticals, a company dedicated to developing novel CNS therapies, has appointed Christopher Burnley chief business officer. Mr Burnley was previously a founder and CEO of VetRx, a biotechnology start-up to develop human biologics for use in companion animals. Before forming VetRx, he served as executive vice-president and chief operating officer of Phenomix Corporation.